448 related articles for article (PubMed ID: 18344322)
1. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
Wang L; Zhou GB; Liu P; Song JH; Liang Y; Yan XJ; Xu F; Wang BS; Mao JH; Shen ZX; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4826-31. PubMed ID: 18344322
[TBL] [Abstract][Full Text] [Related]
2. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
[TBL] [Abstract][Full Text] [Related]
3. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
[TBL] [Abstract][Full Text] [Related]
4. Single-cell transcriptomics profiling the compatibility mechanism of As
Zhang X; Chen H; Huang X; Xu H; Li Y; Yuan H; Yu J; Gao Y
Biomed Pharmacother; 2022 Jul; 151():113182. PubMed ID: 35643069
[TBL] [Abstract][Full Text] [Related]
5. Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cells.
Chen S; Fang Y; Ma L; Liu S; Li X
Int J Oncol; 2012 Apr; 40(4):1089-96. PubMed ID: 22134377
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.
Rego EM; He LZ; Warrell RP; Wang ZG; Pandolfi PP
Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10173-8. PubMed ID: 10954752
[TBL] [Abstract][Full Text] [Related]
7. Understanding the molecular pathogenesis of acute promyelocytic leukemia.
Lo-Coco F; Hasan SK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):3-9. PubMed ID: 24907012
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
[TBL] [Abstract][Full Text] [Related]
9. TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.
Li K; Wang F; Cao WB; Lv XX; Hua F; Cui B; Yu JJ; Zhang XW; Shang S; Liu SS; Yu JM; Han MZ; Huang B; Zhang TT; Li X; Jiang JD; Hu ZW
Cancer Cell; 2017 May; 31(5):697-710.e7. PubMed ID: 28486108
[TBL] [Abstract][Full Text] [Related]
10. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
11. Arsenic sulfide promotes apoptosis in retinoid acid resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein.
Tian Y; Liu Y; He P; Liu F; Zhou N; Cheng X; Shi L; Zhu H; Zhao J; Wang Y; Zhang M
PLoS One; 2014; 9(1):e83184. PubMed ID: 24454695
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
[TBL] [Abstract][Full Text] [Related]
14. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
15. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
[TBL] [Abstract][Full Text] [Related]
16. [Pathogenesis of Acute Promyelocytic Leukemia].
Matsushita H
Rinsho Byori; 2015 May; 63(5):631-42. PubMed ID: 26524903
[TBL] [Abstract][Full Text] [Related]
17. A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
Xie Q; Yu L; Wang X; Wu Z; Zhi D; Yang J; Guo Z; Wu T; Sun Y; Zhao L; Ding X; Khan A; Li H
Pak J Pharm Sci; 2019 May; 32(3):957-962. PubMed ID: 31278706
[TBL] [Abstract][Full Text] [Related]
18. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells.
Yan H; Peng ZG; Wu YL; Jiang Y; Yu Y; Huang Y; Zhu YS; Zhao Q; Chen GQ
Haematologica; 2005 Dec; 90(12):1607-16. PubMed ID: 16330433
[TBL] [Abstract][Full Text] [Related]
20. Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
Misra S; Selvam AK; Wallenberg M; Ambati A; Matolcsy A; Magalhaes I; Lauter G; Björnstedt M
Oncotarget; 2016 Nov; 7(46):74686-74700. PubMed ID: 27732960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
